Novel radiomic analysis on bi-parametric MRI for characterizing differences between MR non-visible and visible clinically significant prostate cancer

• DOI: 10.1016/j.ejro.2023.100496
• Publication Date: 2023-06-13T04:54:56Z
• Authors: Lin Li; Rakesh Shiradkar; Sree Harsha Tirumani; Leonardo Kayat Bi...; Pingfu Fu; Amr Mahran; Christina Buzzy; Phillip D. Stricker; Ardeshir R. Rasti...; Cristina Magi-Gal...; Lee Ponsky; Eric Klein; Andrei S. Purysko; Anant Madabhushi
• Keywords: Medical physics. Medical radiology. Nuclear medicine; Clinically significant prostate cancer; R895-920; Radiomic; Article; 3. Good health; MR non-visible

around one third of clinically significant prostate cancer (CsPCa) foci are reported to be MRI non-visible (MRI─).To quantify the differences between MR visible (MRI+) and MRI─ CsPCa using intra- peri-lesional radiomic features on bi-parametric (bpMRI).This retrospective multi-institutional study comprised 164 patients with pre-biopsy 3T multi-parametric from 2014 2017. The referred lesions PI-RADS v2 score < 3 but ISUP grade group > 1. Three experienced radiologists were involved in annotating assignment. validation set (Dv) 52 a single institution, remaining 112 used for training (Dt). 200 extracted intra-lesional regions bpMRI.Logistic regression least absolute shrinkage selection operator (LASSO) 10-fold cross-validation was applied Dt identify associated MRI+ generate corresponding risk scores RMRI─ RMRI+. RbpMRI further generated by integrating Statistical significance determined Wilcoxon signed-rank test.Both bpMRI Haralick CoLlAGe significantly (p 0.05). Intra-lesional ADC different among yielded highest AUC 0.82 (95 % CI 0.72-0.91) compared AUCs RMRI+ 0.76 0.63-0.89), 0.58 0.50-0.72) Dv. correctly reclassified 10 out 14 Dv.Our preliminary results demonstrated that both CsPCa. These could assist identification bpMRI.